![Phase I AMG 701 - Capsule Summary Slidesets - Myeloma - 2020 ASH Annual Meeting - Oncology - Clinical Care Options Phase I AMG 701 - Capsule Summary Slidesets - Myeloma - 2020 ASH Annual Meeting - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/conferences/hematology-2020/myeloma/cco_hematology_2020_181_thumb.png?rev=cb04b68333a549fa95b37a2ce3c49e8b&h=200&as=1&hash=2FDB309DF3C065235AABD5CB1B09C56CC426ABA4)
Phase I AMG 701 - Capsule Summary Slidesets - Myeloma - 2020 ASH Annual Meeting - Oncology - Clinical Care Options
![CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma: Molecular Therapy CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma: Molecular Therapy](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a8649da2-8692-4f38-973b-80a82bc932ec/gr1_lrg.jpg)
CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma: Molecular Therapy
![Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma | Leukemia Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma | Leukemia](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41375-020-0834-9/MediaObjects/41375_2020_834_Fig1_HTML.png)
Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma | Leukemia
![Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma | Semantic Scholar Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/afaaee6ef1cdcaa32fd5f68c1da57399a3dccc34/3-Figure2-1.png)
Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma | Semantic Scholar
![Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma | Journal of Hematology & Oncology | Full Text Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-020-01001-1/MediaObjects/13045_2020_1001_Fig1_HTML.png)
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma | Journal of Hematology & Oncology | Full Text
![A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d0668b16-6f13-4a1b-99c6-7416a2f7b1b3/ctm2346-fig-0002-m.jpg)
A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library
![Mechanisms of action of anti-BCMA mAb, antibody drug conjugates and... | Download Scientific Diagram Mechanisms of action of anti-BCMA mAb, antibody drug conjugates and... | Download Scientific Diagram](https://www.researchgate.net/publication/353076759/figure/fig2/AS:1043290698821633@1625751294867/Mechanisms-of-action-of-anti-BCMA-mAb-antibody-drug-conjugates-and-bispecific.png)
Mechanisms of action of anti-BCMA mAb, antibody drug conjugates and... | Download Scientific Diagram
![Summary clinical study results of anti-BCMA ADC, BiTE, and bispecific... | Download Scientific Diagram Summary clinical study results of anti-BCMA ADC, BiTE, and bispecific... | Download Scientific Diagram](https://www.researchgate.net/publication/342042028/figure/tbl2/AS:903665472786435@1592462046938/Summary-clinical-study-results-of-anti-BCMA-ADC-BiTE-and-bispecific-antibodies.png)
Summary clinical study results of anti-BCMA ADC, BiTE, and bispecific... | Download Scientific Diagram
![A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/e2cdb767-eb9f-439b-b36d-d44a6decee35/ctm2346-gra-0001-m.jpg)
A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library
![Frontiers | Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions | Immunology Frontiers | Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions | Immunology](https://www.frontiersin.org/files/Articles/516225/fimmu-11-00501-HTML/image_m/fimmu-11-00501-g001.jpg)
Frontiers | Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions | Immunology
CD269 (BCMA) Antibody, anti-human, REAfinity™ | Recombinant antibodies | MACS Antibodies | Products | Miltenyi Biotec | Suomi
![Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment - ScienceDirect Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1535610817300168-fx1.jpg)
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment - ScienceDirect
![B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches | Leukemia B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches | Leukemia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-020-0734-z/MediaObjects/41375_2020_734_Fig3_HTML.png)
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches | Leukemia
![BCMA targeted therapy! GSK antibody drug conjugates apply for sale at the end of the year – Creative Biolabs ADC Blog BCMA targeted therapy! GSK antibody drug conjugates apply for sale at the end of the year – Creative Biolabs ADC Blog](https://www.creative-biolabs.com/blog/adc/wp-content/uploads/2019/04/2.jpg)
BCMA targeted therapy! GSK antibody drug conjugates apply for sale at the end of the year – Creative Biolabs ADC Blog
![B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches | Leukemia B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches | Leukemia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-020-0734-z/MediaObjects/41375_2020_734_Fig2_HTML.png)
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches | Leukemia
![Frontiers | Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions | Immunology Frontiers | Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions | Immunology](https://www.frontiersin.org/files/MyHome%20Article%20Library/516225/516225_Thumb_400.jpg)
Frontiers | Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions | Immunology
![Cancers | Free Full-Text | The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond | HTML Cancers | Free Full-Text | The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond | HTML](https://www.mdpi.com/cancers/cancers-13-04701/article_deploy/html/images/cancers-13-04701-g001.png)